Merck to expand Cali viral and gene therapy plant

By Gareth Macdonald

- Last updated on GMT

Merck's former Sigma-Aldrich facility in Carlsbad, California
Merck's former Sigma-Aldrich facility in Carlsbad, California
Germany's Merck has announced its intention to expand its viral and gene therapy production facility in Carlsbad, California.

The firm cited customer demand as the main driver for the investment, explaining that the plan was to add 21,000 square feet of production space, two fill/finish suites and clean rooms.

The expansion – which Merck said will increase current capacity by 90% - is due to be completed this year will support clinical and commercial production.

Merck said the expanded facility will work with both its cell-banking operations in Rockville, Maryland and its viral and gene therapy production capacity in Glasgow, Scotland.

The Carlsbad facility became part of Merck's manufacturing network through the acquisition of Sigma-Aldrich in 2014​.

News of the expansion follows just days after Merck announced it had upped bioreactor capacity at its facility in Martillac, France in a move designed to broaden its biologics manufacturing offering.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers